Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,019 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Interventions
AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Santa Monica, California • Santa Rosa, California + 11 more
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Not listed
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Head and Neck Cancer, Carcinoma, Squamous Cell
Interventions
ZD-1839, Cisplatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Stanford, California
Conditions
Head and Neck Carcinoma
Interventions
Behavioral Intervention, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Portland, Oregon
Conditions
Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions
5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
Davis, California • Duarte, California • South Pasadena, California + 1 more
Conditions
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Interventions
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Drug
Lead sponsor
Kineta Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cisplatin, Carboplatin, IMRT (Intensity-Modulated Radiation Therapy), Boost Radiation to Hypoperfused Volumes
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan
Conditions
Oropharynx Cancer
Interventions
Radiation therapy (5 days for 7 weeks), Radiation therapy (5 days for 6 weeks), Cisplatin
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cancer
Interventions
Oral lapatinib tablets or placebo tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
Conditions
Head and Neck Cancer
Interventions
Panitumumab IRDye 800, da Vinci Firefly, IMAGE1 + ICG Hopkins telescope and/or VITOM
Drug · Device
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Stanford, California
Conditions
Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell), Thyroid Cancer, Papillary, BRAF V600E Mutation Positive
Interventions
I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
Interventions
SEA-TGT, sasanlimab, brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more
Conditions
Advanced MTAP-null Solid Tumors
Interventions
Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Oxnard, California + 24 more
Conditions
Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, Hypopharynx
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions
Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more
Conditions
Oral Cancer
Interventions
Not listed
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Head and Neck Cancer
Interventions
porfiromycin, radiation therapy
Drug · Radiation
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Peoria, Illinois • Dallas, Texas + 1 more
Conditions
Esophageal Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
71
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 52 more
Conditions
Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Durham, North Carolina • San Antonio, Texas
Conditions
Head and Neck Cancer
Interventions
ADP-A2M4 in combination with pembrolizumab.
Genetic
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • San Diego, California • Kansas City, Kansas + 5 more
Conditions
Oral Leukoplakia
Interventions
Lozenge Intake
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Interventions
docetaxel, cisplatin, 5-FU, IMRT, cetuximab, carboplatin
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 1Phase 2 Interventional

APG-115 in Salivary Gland Cancer Trial

NCT03781986
Conditions
Malignant Salivary Gland Cancer, Salivary Gland Cancer
Interventions
APG-115, Carboplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • Ann Arbor, Michigan
Conditions
Advanced Bulky Malignancies
Interventions
Spatially Fractioned Radiation Therapy, Treatment Group 1, Standard radiation
Radiation
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Akron, Ohio